Articles related to KIDNEY CANCER/RCC

A recent study from Fox Chase Cancer Center has revealed that as many as 23% of cystic renal masses may carry high-grade, or aggressive, disease. This finding challenges the prevailing assumption of their low-risk nature and underscores the need for more discerning diagnostic and treatment strategies.

Explore how the landscape of RCC treatment is evolving with a focus on inclusivity and patient-centric approaches.

Discover how SABR is setting a new standard in the treatment of inoperable renal cell carcinoma, offering exceptional cancer control with minimal side effects.

Understanding the impact of lymphovascular invasion on overall survival in RCC patients is crucial for surgical decision-making and postoperative care.

Innovations in mRCC management are accelerating, and significant shifts have already begun with the ODYSSEY RCC study and the first-ever comprehensive ASCO guidelines for metastatic clear-cell RCC – read on to stay ahead of the curve.

Discover a holistic perspective on advanced bladder and renal cell cancers management, encompassing everything from pathogenesis to adverse event mitigation. Let’s dive into the “Advanced Bladder and Renal Cell Cancers Management” webcast, released on April 30, 2023, offering valuable 1.00 ANCC contact hour, inclusive of 0.75 pharmacology hours. Presented by expert Mary W. Dunn, MSN, RN, OCN, NP-C from the University of North Carolina, this program targets oncology nurses, nurse navigators, advanced nursing providers, and nurses from other cancer-related subspecialties. It remains available until April 30, 2024, leaving ample time to gain this crucial knowledge. Primarily, this webcast zeroes in on bladder cancer (BC), a malignancy notorious for its high mortality rate, and renal cell carcinoma (RCC), a top-10 common cancer. Unfortunately, BC’s 5% survival rate for metastatic disease cases paints a grim picture. Luckily, hope emerges in the form of novel therapeutic agents for advanced, recurrent, and metastatic BC and RCC. Next, the program navigates through the pathogenesis of these cancers. Equipped with this knowledge, healthcare providers can better understand the intricacies of disease progression. As the treatment landscape rapidly evolves, so does the complexity in selection, sequencing, and adverse event (AE) management. Thus, the webcast outlines how to […]